N4 Pharma Cash Flow Statement

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2016 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2016 - 2019
Net Income	-1.06	-1.27	-1.03	-1.54	-1.3	Upgrade
Asset Writedown & Restructuring Costs	0.06	-	-	-	-	Upgrade
Stock-Based Compensation	0.01	0	0.02	0.02	0	Upgrade
Other Operating Activities	-0.01	0.01	0.35	-0.3	-0.14	Upgrade
Change in Accounts Receivable	-0.01	0.04	-0.04	0.01	-0.03	Upgrade
Change in Accounts Payable	0.04	0	-0.13	0.04	0.09	Upgrade
Operating Cash Flow	-0.97	-1.21	-0.83	-1.77	-1.38	Upgrade
Cash Acquisitions	-	0	-	-	-	Upgrade
Investing Cash Flow	-	0	-	-	-	Upgrade
Issuance of Common Stock	0.63	0.35	1.05	-	3.97	Upgrade
Other Financing Activities	-0.06	-0.03	-0.09	0	0	Upgrade
Financing Cash Flow	0.57	0.32	0.96	0	3.97	Upgrade
Net Cash Flow	-0.4	-0.89	0.14	-1.77	2.59	Upgrade
Cash Income Tax Paid	-	-0.16	-0.51	-	-0.12	Upgrade
Levered Free Cash Flow	-0.68	-0.82	-0.54	-1.38	-1.03	Upgrade
Unlevered Free Cash Flow	-0.68	-0.82	-0.54	-1.38	-1.03	Upgrade
Change in Net Working Capital	-0.08	-0.06	-0.18	0.24	0.06	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.